Cédric Langhi1, Tyler J Marquart1, Ryan M Allen1, Angel Baldán2. 1. Edward A. Doisy Department of Biochemistry & Molecular Biology, and Center for Cardiovascular Research, Saint Louis University, Saint Louis, MO 63104, United States. 2. Edward A. Doisy Department of Biochemistry & Molecular Biology, and Center for Cardiovascular Research, Saint Louis University, Saint Louis, MO 63104, United States. Electronic address: abaldan1@slu.edu.
Abstract
BACKGROUND & AIMS: Perilipin-5 (PLIN5) is a member of the perilipin family of lipid droplet (LD)-associated proteins. PLIN5 is expressed in oxidative tissues including the liver, and is critical during LD biogenesis. Studies showed that statins reduce hepatic triglyceride contents in some patients with non-alcoholic fatty liver disease and in rodent models of diet-induced hepatosteatosis. Whether statins alter triglyceride synthesis, storage, and/or utilization within the hepatocyte is unknown, though. Here we tested the hypothesis that statins alter the metabolism of LD in the hepatocyte during physiological conditions, such as fasting-induced steatosis. METHODS: Mice were gavaged with saline or atorvastatin, and the expression of LD-associated genes was determined in fed and fasted animals. The accumulation of triglycerides and LD was studied in mouse or human primary hepatocytes in response to statins, and following knock-down of SREBP2 or PLIN5. RESULTS: We show that statins decrease the levels of PLIN5, but not other LD-associated genes, in both mouse liver and mouse/human primary hepatocytes, which is paralleled by a significant reduction in both intracellular triglycerides and the number of LD. We identify an atypical negative sterol regulatory sequence in the proximal promoter of mouse/human PLIN5 that recruits the transcription factor SREBP2 and confers response to statins. Finally, we show that the statin-dependent reduction of hepatocyte triglyceride contents is mimicked by partial knock-down of PLIN5; conversely, ectopic overexpression of PLIN5 reverts the statin effect. CONCLUSIONS: PLIN5 is a physiological regulator of triglyceride metabolism in the liver, and likely contributes to the pleiotropic effects of statins.
BACKGROUND & AIMS:Perilipin-5 (PLIN5) is a member of the perilipin family of lipid droplet (LD)-associated proteins. PLIN5 is expressed in oxidative tissues including the liver, and is critical during LD biogenesis. Studies showed that statins reduce hepatic triglyceride contents in some patients with non-alcoholic fatty liver disease and in rodent models of diet-induced hepatosteatosis. Whether statins alter triglyceride synthesis, storage, and/or utilization within the hepatocyte is unknown, though. Here we tested the hypothesis that statins alter the metabolism of LD in the hepatocyte during physiological conditions, such as fasting-induced steatosis. METHODS:Mice were gavaged with saline or atorvastatin, and the expression of LD-associated genes was determined in fed and fasted animals. The accumulation of triglycerides and LD was studied in mouse or human primary hepatocytes in response to statins, and following knock-down of SREBP2 or PLIN5. RESULTS: We show that statins decrease the levels of PLIN5, but not other LD-associated genes, in both mouse liver and mouse/human primary hepatocytes, which is paralleled by a significant reduction in both intracellular triglycerides and the number of LD. We identify an atypical negative sterol regulatory sequence in the proximal promoter of mouse/humanPLIN5 that recruits the transcription factor SREBP2 and confers response to statins. Finally, we show that the statin-dependent reduction of hepatocyte triglyceride contents is mimicked by partial knock-down of PLIN5; conversely, ectopic overexpression of PLIN5 reverts the statin effect. CONCLUSIONS:PLIN5 is a physiological regulator of triglyceride metabolism in the liver, and likely contributes to the pleiotropic effects of statins.
Authors: T Heinemeyer; E Wingender; I Reuter; H Hermjakob; A E Kel; O V Kel; E V Ignatieva; E A Ananko; O A Podkolodnaya; F A Kolpakov; N L Podkolodny; N A Kolchanov Journal: Nucleic Acids Res Date: 1998-01-01 Impact factor: 16.971
Authors: C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes Journal: Lancet Date: 2005-09-27 Impact factor: 79.321
Authors: Ulrika Edvardsson; Anna Ljungberg; Daniel Lindén; Lena William-Olsson; Helena Peilot-Sjögren; Andrea Ahnmark; Jan Oscarsson Journal: J Lipid Res Date: 2005-11-10 Impact factor: 5.922
Authors: Núria Roglans; Elena Sanguino; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez Journal: J Pharmacol Exp Ther Date: 2002-07 Impact factor: 4.030
Authors: Anastasia Asimakopoulou; Kathrin M Engel; Nikolaus Gassler; Thilo Bracht; Barbara Sitek; Eva M Buhl; Stavroula Kalampoka; Manuela Pinoé-Schmidt; Josef van Helden; Jürgen Schiller; Ralf Weiskirchen Journal: Cells Date: 2020-05-28 Impact factor: 6.600